Nyrada Inc – CEO Remuneration Update
Sydney, 27 October 2022: Nyrada Inc (ASX: NYR) (“Nyrada” or “the Company”) a preclinical stage, drug development company specialising in… Read more
Sydney, 27 October 2022: Nyrada Inc (ASX: NYR) (“Nyrada” or “the Company”) a preclinical stage, drug development company specialising in… Read more
Nyrada Inc. released its September quarterly report this morning – ASX release attached. The most significant point which Canary would… Read more
Sydney, 18 October 2022: Nyrada Inc (ASX: NYR) (“Nyrada” or “the Company”) a preclinical stage, drug development company specialising in… Read more
Nyrada Inc. (ASX: NYR) has had its NYX-PCSK9i Efficacy Study Published in Journal of Lipid Research, a highly regarded publication… Read more
Nyrada Inc (ASX: NYR) is pleased to provide investors with the attached presentation, which will be given by Nyrada CEO,… Read more
Nyrada Inc (ASX: NYR) is pleased to provide shareholders and the market generally with the attached presentation that will be… Read more
Highlights: • Research and development costs of $1.8M as Nyrada’s lead preclinical programs advance (FY2021: $2.2M). • Robust cash position… Read more
Nyrada : Improving lives through innovation.
• Global pharmaceutical leader, Dr. Gisela Mautner appointed as Non-Executive Director • Dr. Mautner brings over 20 years of extensive… Read more